Navigating nephrotoxicity: insights from 4 years of [177Lu]Lu-DOTA-TATE therapy at our institution

被引：0
|
作者：
Sousa, E. [1 ]
Sousa, R. [2 ]
Fraga, D. [1 ]
Carvalho, I. P. [1 ]
Vitorino, I. [1 ]
Rombo, D. [1 ]
Aco, J. [1 ]
Jorge, P. [1 ]
Salgado, L. [1 ]
机构：
[1] Inst Portugues Oncol Francisco Gentil, Lisbon, Portugal
[2] Hosp Forcas Armadas, Lisbon, Portugal
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
PRRT;
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0591
引用
收藏
页码：S667 / S667
页数：1
相关论文
共 50 条
  • [21] Enhancing [177Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics
    Cheng, Jordan
    Zink, Joke
    O'Neill, Edward
    Cornelissen, Bart
    Nonnekens, Julie
    Livieratos, Lefteris
    Terry, Samantha Y. A.
    EJNMMI RESEARCH, 2024, 14 (01):
  • [22] Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE-A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
    Durma, Adam Daniel
    Saracyn, Marek
    Kolodziej, Maciej
    Jozwik-Plebanek, Katarzyna
    Dmochowska, Beata
    Kapusta, Waldemar
    Zmudzki, Wawrzyniec
    Mroz, Adrianna
    Kos-Kudla, Beata
    Kaminski, Grzegorz
    CANCERS, 2023, 15 (22)
  • [23] Relationship between absorbed dose and response in neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE
    Warfvinge, C. F.
    Gustafsson, J.
    Roth, D.
    Tennvall, J.
    Svensson, J.
    Bernhardt, P.
    Akesson, A.
    Wieslander, E.
    Sundlov, A.
    Gleisner, Sjogreen K.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 221 - 221
  • [24] Kidney dosimetry in [ 177 Lu]Lu-DOTA-TATE therapy based on multiple small VOIs
    Kapidzic, Selma Curkic
    Gustafsson, Johan
    Larsson, Erik
    Jessen, Lovisa
    Gleisner, Katarina Sjogreen
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2024, 120
  • [25] Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats
    Zellmer, Johannes
    Yen, Hsi-Yu
    Kaiser, Lena
    Mille, Erik
    Gildehaus, Franz Josef
    Boening, Guido
    Steiger, Katja
    Hacker, Marcus
    Bartenstein, Peter
    Todica, Andrei
    Haug, Alexander R.
    Ilhan, Harun
    EJNMMI RESEARCH, 2020, 10 (01)
  • [26] Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats
    Johannes Zellmer
    Hsi-Yu Yen
    Lena Kaiser
    Erik Mille
    Franz Josef Gildehaus
    Guido Böning
    Katja Steiger
    Marcus Hacker
    Peter Bartenstein
    Andrei Todica
    Alexander R. Haug
    Harun Ilhan
    EJNMMI Research, 10
  • [27] Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
    del Olmo-Garcia, Maria I.
    Prado-Wohlwend, Stefan
    Bello, Pilar
    Segura, Angel
    Merino-Torres, Juan F.
    CANCERS, 2022, 14 (03)
  • [28] S-phase enrichment by hydroxyurea treatment enhances [177Lu]Lu-DOTA-TATE uptake in vitro
    Cheng, J.
    Livieratos, L.
    Terry, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S57 - S57
  • [29] Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [177Lu]Lu-OPS201 Compared to the Agonist [177Lu]Lu-DOTA-TATE
    Mansi, Rosalba
    Plas, Pascale
    Vauquelin, Georges
    Fani, Melpomeni
    PHARMACEUTICALS, 2021, 14 (12)
  • [30] Personalized, dosimetry-based PRRT therapy in patients with neuroendocrine tumors using [177Lu]Lu-DOTA-TATE or [177Lu]Lu/[90Y]Y-DOTA-TATE mixture - the initial results of DUONEN multicenter study
    Opalinska, M.
    Kaminski, G.
    Dedecjus, M.
    Kowalska, A.
    Kolodziej, M.
    Saracyn, M.
    Gasior-Perczak, D.
    Lenda-Tracz, W.
    Sowa-Staszczak, A.
    Borkowska, A.
    Budzynska, A.
    Kubik, A.
    Chalewska, W.
    Kacperski, K.
    Szubstarska, P.
    Garnuszek, P.
    Mikolajczak, R.
    Hubalewska-Dydejczyk, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S314 - S314
12345